Recombinant Raphanus sativus AFP2 Protein ，His & SUMO

AFP2, or alpha-fetoprotein isoform 2, is a variant of the well-known alpha-fetoprotein, a glycoprotein synthesized primarily by the liver and yolk sac during fetal development. Research on AFP2 has gained significant attention due to its potential applications in oncology and immunology. Unlike its counterpart, AFP1, which is often associated with liver cancer and certain fetal disorders, AFP2 emerges as a candidate for diagnostics and therapeutic targets due to its unique structural and functional properties. Studies have indicated that AFP2 can influence tumor progression and immune response, providing insights into tumor microenvironments. Its expression patterns in various cancers suggest a role in tumor marker development, where elevated levels may indicate malignancies. Furthermore, understanding the molecular mechanisms regulating AFP2 could lead to innovative strategies in cancer treatment and immunotherapy, potentially enhancing the efficacy of existing therapies. As researchers delve deeper into the implications of AFP2, it becomes imperative to explore its interactions at the cellular level and its contributions to the physiology of both normal and cancerous tissues, opening new avenues for clinical applications and personalized medicine. The ongoing investigation into AFP2 is crucial for elucidating its role in disease progression and for harnessing its potential in therapeutic interventions.